Related references
Note: Only part of the references are listed.Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium
Brent W. Sutherland et al.
CANCER RESEARCH (2008)
Endogenous sex hormones and the risk of prostate cancer: A prospective study
Jocelyn M. Weiss et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations
Sharon Maor et al.
CANCER LETTERS (2007)
Insulin-like growth factors and ovarian cancer risk: A nested case-control study in three cohorts
Shelley S. Tworoger et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer
Laura Baglietto et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis
Kai-Da Wu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Preclinical in vivo study of new insulin-like growth factor-1 receptor -: Specific inhibitor in Ewing's sarcoma
Maria C. Manara et al.
CLINICAL CANCER RESEARCH (2007)
Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: A preliminary report
O. Shevah et al.
GROWTH HORMONE & IGF RESEARCH (2007)
The role of the IGF system in cancer growth and metastasis: Overview and recent insights
Amir Abbas Samani et al.
ENDOCRINE REVIEWS (2007)
The IGF axis in prostate cancer
S. Monti et al.
CURRENT PHARMACEUTICAL DESIGN (2007)
The insulin-like growth factor 1 receptor in cancer: Old focus, new future
Hermien Hartog et al.
EUROPEAN JOURNAL OF CANCER (2007)
Disrupting insulin-like growth factor signaling as a potential cancer therapy
Deepali Sachdev et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer
Charles J. Ryan et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2007)
IGF1R signalling and its inhibition
J. Riedemann et al.
ENDOCRINE-RELATED CANCER (2006)
Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium
Adrienne S. McCampbell et al.
CLINICAL CANCER RESEARCH (2006)
A phase I dose-escalation study of weekly IMC-A12, a fully human insulin like growth factor-1 receptor (IGF-IR) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer
C. Higano et al.
EJC SUPPLEMENTS (2006)
A phase I trial incorporating the pharmacodynamic (PD) study of circulating tumour cells (CTC) of CP-751,871 (C), a monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R), in combination with docetaxel (D) in patients (p) with advanced cancer
P. C. Fong et al.
EJC SUPPLEMENTS (2006)
Interaction of IGF signaling and the androgen receptor in prostate cancer progression
Jennifer D. Wu et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2006)
Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of ana plastic thyroid carcinoma
Zhuoying Wang et al.
CLINICAL CANCER RESEARCH (2006)
The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action
Haim Werner et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2006)
IGF-1, IGFBP-3 and breast cancer risk in women:: The European Prospective Investigation into Cancer and Nutrition (EPIC)
S. Rinaldi et al.
ENDOCRINE-RELATED CANCER (2006)
Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II
Eva S. Schemhammer et al.
ENDOCRINE-RELATED CANCER (2006)
Blockade of IGF-1 receptor tyrosine kinase has antlineoplastic effects in hepatocellular carcinoma cells
M Höpfner et al.
BIOCHEMICAL PHARMACOLOGY (2006)
Insulin-like growth factor (IGF) family and prostate cancer
C. Gennigens et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2006)
Immunohistochemical prognostic factors in resected colorectal lung metastases using tissue microarray analysis
S Shiono et al.
EJSO (2006)
Expression of IGF-I, IGF-II, and IGF-IR in gallbladder carcinoma.: A systematic analysis including primary and corresponding metastatic tumours
P Kornprat et al.
JOURNAL OF CLINICAL PATHOLOGY (2006)
Insulin-like growth factor receptor I targeting in epithelial ovarian cancer
WH Gotlieb et al.
GYNECOLOGIC ONCOLOGY (2006)
Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor
Ana S. Martins et al.
CLINICAL CANCER RESEARCH (2006)
In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417
P Haluska et al.
CANCER RESEARCH (2006)
Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade
YD Liao et al.
HUMAN PATHOLOGY (2005)
Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-B
SP Mathur et al.
GYNECOLOGIC ONCOLOGY (2005)
Blocking insulin-like growth factor-I receptor as a strategy for targeting cancer
F Hofmann et al.
DRUG DISCOVERY TODAY (2005)
Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer
AM Burger et al.
EUROPEAN JOURNAL OF CANCER (2005)
Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors
K Scotlandi et al.
CANCER RESEARCH (2005)
In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors
JD Wu et al.
CLINICAL CANCER RESEARCH (2005)
A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk
NE Allen et al.
BRITISH JOURNAL OF CANCER (2005)
Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871
BD Cohen et al.
CLINICAL CANCER RESEARCH (2005)
High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer
RA Sayer et al.
GYNECOLOGIC ONCOLOGY (2005)
A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts
L Goetsch et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer
MA Rochester et al.
CANCER GENE THERAPY (2005)
Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis
AG Renehan et al.
LANCET (2004)
Insulin-like growth factor (IGF)-system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk
DW Voskuil et al.
BREAST CANCER RESEARCH AND TREATMENT (2004)
The new kid on the block(ade) of the IGF-1 receptor (vol 5,pg 201, 2004)
D LeRoith et al.
CANCER CELL (2004)
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors
CS Mitsiades et al.
CANCER CELL (2004)
In vivo antitumor activity of NVP-AEW541 -: A novel, potent, and selective inhibitor of the IGF-IR kinase
C García-Echeverría et al.
CANCER CELL (2004)
Igf-I and breast cancer: A meta-analysis
RH Shi et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Insulin-like growth factor (IGF)-I and IGF-binding protein 3 and the risk of premenopausal breast cancer: A meta-analysis of literature
A Sugumar et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: A randomized phase II study
MA Dimopoulos et al.
UROLOGY (2004)
Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth
A Girnita et al.
CANCER RESEARCH (2004)
The igf-1 receptor in cancer biology
R Baserga et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk
E Weiderpass et al.
BRITISH JOURNAL OF CANCER (2003)
Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse
DG Barcena et al.
PROSTATE (2003)
The insulin-like growth factor/insulin system in epithelial ovarian cancer
KR Kalli et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2003)
Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk
H Zhao et al.
JOURNAL OF UROLOGY (2003)
Insulin-like growth factor II in gynecological cancers: A preliminary study
SP Mathur et al.
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY (2003)
Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor
GO Hellawell et al.
BJU INTERNATIONAL (2003)
Endometrial cancer and the IGF system: A case-control study in Greece
E Petridou et al.
ONCOLOGY (2003)
Circulating levels of insulin-like growth factor-I and risk of ovarian cancer
A Lukanova et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden
R Palmqvist et al.
GUT (2002)
Over-expression of insulin-like growth factor binding protein-related protein-1 (IGFBP-rP1/mac25) in the M12 prostate cancer cell line alters tumor growth by a delay in G1 and cyclin A associated apoptosis
CC Sprenger et al.
ONCOGENE (2002)
The relationship of circulating insulin-like growth factor 1, its binding protein-3, prostate-specific antigen and C-reactive protein with disease stage in prostate cancer
Z Latif et al.
BJU INTERNATIONAL (2002)
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)
YH Lu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Distinct and overlapping functions of insulin and IGF-I receptors
J Nakae et al.
ENDOCRINE REVIEWS (2001)
Insulin-like growth factor-I and prostate cancer: a meta-analysis
R Shi et al.
BRITISH JOURNAL OF CANCER (2001)
Delineation of prognostic biomarkers in prostate cancer
SM Dhanasekaran et al.
NATURE (2001)
Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas
DW Andrews et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Loss of heterozygosity at the mannose 6-phosphate/insulin-like growth factor 2 receptor locus: a frequent but late event in adrenocortical tumorigenesis
S Leboulleux et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2001)
Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk:: a prospective study
P Stattin et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
New concepts in regulation and function of the insulin-like growth factors: implications for understanding normal growth and neoplasia
H Werner et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2000)
Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice
J DiGiovanni et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Hormonal predictors of prostate cancer: A meta-analysis
T Shaneyfelt et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Crosstalk between the insulin-like growth factors and estrogens in breast cancer
D Yee et al.
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2000)
Share Paper
